Genes & Diseases

Genes & Diseases

Volume 10, Issue 1, January 2023, Pages 89-100
Genes & Diseases

Review Article
The IL13α 2R paves the way for anti-glioma nanotherapy

https://doi.org/10.1016/j.gendis.2021.08.006Get rights and content
Under a Creative Commons license
open access

Abstract

Glioblastoma (GBM) is one of the most aggressive (grade IV) gliomas characterized by a high rate of recurrence, resistance to therapy and a grim survival prognosis. The long-awaited improvement in GBM patients’ survival rates essentially depends on advances in the development of new therapeutic approaches. Recent preclinical studies show that nanoscale materials could greatly contribute to the improvement of diagnosis and management of brain cancers. In the current review, we will discuss how specific features of glioma pathobiology can be employed for designing efficient targeting approaches. Moreover, we will summarize the main evidence for the potential of the IL-13R alpha 2 receptor (IL13α2R) targeting in GBM early diagnosis and experimental therapy.

Keywords

Brain tumor
Experimental therapy
GBM
IL-13Rα2
Nanoparticles
Receptor
Viral vectors

Cited by (0)

Peer review under responsibility of Chongqing Medical University.